It is all about networking (business 101)Something to think about
Dr Jackie Fairley was appointed as an Independent Non-Executive Director of Mirrabooka Investments Ltd, on 15 February 2018.
Mirrabooka Investments Ltd take a new position and buys an initial 2,500,000 shares in Starpharma that same financial year
Mirrabooka Investments Ltd is an investment company incorporated in Australia. The objective of the Company is to provide capital appreciation and income over the medium to long-term. The Company invests in small and medium-sized companies located in Australian and New Zealand that are smaller than the Australian top 50 listed companies
Annual Report 2018Mirrabooka takes an initial investment of
2,500,000 shares in Starpharma
Jackie currently sits on the board of the Melbourne Business School and is Chair of its Remuneration and Nomination Committee. She is a non-executive director of listed investment company
Mirrabooka Investments Limited, a member of the Federal Government’s Commonwealth Science Council, and is a past member of the Federal Government’s Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council. She is also on the Investment Committee of the Carnegie Innovation Fund.
Annual Report 2019Mirrabooka tops up its initial holdings to
3,979,571 shares in Starphama
Jackie currently sits on the board of the Melbourne Business School, and is a non-executive director of listed investment company
Mirrabooka Investments Limited. She is a past member of the Federal Government’s Commonwealth Science Council and Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council.
Starpharma’s CEO also sits on the board of listed small-cap investment company Mirrabooka as a non-executive director.
This external post exposes both Dr Fairley and Starpharma to insights from institutional investors and further extends the company’s network and provides her with a different vantage point.Dr Fairley remains fully committed to her CEO role at Starpharma and the Board has carefully considered the time commitment to ensure her leadership of Starpharma is not impacted.
(20min delay)